Management of acromegaly in Latin America: expert panel recommendations - Wikidata - awgldk - TriplyDB

Management of acromegaly in Latin America: expert panel recommendations

Management of acromegaly in Latin America: expert panel recommendations

http://www.wikidata.org/entity/Q33794388

about

Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report The role of primary pharmacological therapy in acromegaly.Pituitary adenomas in childhood and adolescence with a focus on intratumoral hemorrhage.Frequency of multiple endocrine neoplasia type 1 in a group of patients with pituitary adenoma: genetic study and familial screening.Medical therapy of acromegaly in Turkey.Aggressive tumors and difficult choices in acromegaly.Acromegaly: role of surgery in the therapeutic armamentarium.Nadir growth hormone after oral glucose overload in obese subjects.Acromegalic patients lost to follow-up: a pilot study.Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression.Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result?Screening for acromegaly in adult patients not reporting enlargement of the extremities, but with arterial hypertension associated with another comorbidity of the disease.Daily life reflections of acromegaly guidelines.Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial.

P2860

Q33592680-13C29E09-D059-472D-9FE4-479DD19BB99F Q37531005-DAB1C61C-43B2-49ED-A2BF-45C9251ECCF8 Q37531036-4E33110E-01E6-4EED-A456-3A5D2699B868 Q37531060-C0F400A8-FCDE-41A4-B3F0-BF02142E4ED4 Q37798655-B831D825-10E8-4A1D-A416-711985D0696A Q38167711-B1C96A7E-28A7-40A8-8F12-BE5564E5AEF4 Q41628092-F1694D6E-D78A-4CDE-B17C-0CB999F184F5 Q42943088-48FFDC5A-8FDE-49A9-B0F6-1368B35DF660 Q43898221-305279F8-E0F4-4DE2-A0B4-F2CF9F60D468 Q44117894-BD5DC6D0-A581-401E-851D-94003F3DA921 Q47773067-CD7914C3-B0D1-42AF-9141-9D389A95B0F2 Q48201657-26B0AEFD-8923-49F4-9AC3-D7B8D5CB5244 Q48427051-7D0A195D-044B-47B6-9EB3-F8199523CAEC Q53765411-3827123A-B4F0-4B5D-888F-BA89EC75D5E0 Q54542028-E7144C6C-6EA3-41F8-985E-53419E8C9B95

P2860

Management of acromegaly in Latin America: expert panel recommendations

http://www.wikidata.org/entity/Q33794388

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Management of acromegaly in Latin America: expert panel recommendations

@ast

Management of acromegaly in Latin America: expert panel recommendations

@en

type

label

Management of acromegaly in Latin America: expert panel recommendations

@ast

Management of acromegaly in Latin America: expert panel recommendations

@en

prefLabel

Management of acromegaly in Latin America: expert panel recommendations

@ast

Management of acromegaly in Latin America: expert panel recommendations

@en

P1433

Q33794388-B988C9DE-434B-4B25-BACE-B0432F581656

P1476

Q33794388-3E9CFA7F-CCDF-4394-986C-B39B4A0E01B6

P2093

Q33794388-0E3B1FBC-B9D5-446C-AA9A-D4CA443E0AED

Q33794388-0E5CD163-9661-4C53-BACB-31BFFCCCBD54

Q33794388-44626ABF-58A2-45AD-9AB6-E2BF8019129A

Q33794388-4FFF1A4D-7EA2-416F-AB9A-3BC60E57ED58

Q33794388-8A5A6A20-3B37-43AC-89DD-3A7EE8CE10AE

Q33794388-9C51489D-A89D-437F-B01F-CCBAB44D8B44

Q33794388-A2854264-F0DF-482C-91F6-6F525538CCD4

Q33794388-CDFB3643-8076-4460-BA53-BCA84B01AEA0

Q33794388-DD16C42D-38DE-4B6D-80D9-B26C70BEDD55

Q33794388-DE78765E-C894-437D-9663-CF2FC6DD5202

P2860

Q33794388-13C10809-34A1-4D60-BBFB-8087B8FAB4AE

Q33794388-143D5E94-DC39-464B-A4DF-F62C4B00CE99

Q33794388-1C6EB984-4702-47B6-BDA2-3C11C8ACE42B

Q33794388-22DE15BF-ADF8-4120-955C-642F2512FB24

Q33794388-27D08DD2-4968-4396-AF0C-12D617569F0F

Q33794388-2AFC9B73-3420-494F-8633-E547E4F52C8F

Q33794388-2CCCA3D4-90E7-4752-9B2D-39E9186BFF5E

Q33794388-3D342D52-48E1-4BFE-9739-B1A140EABDEF

Q33794388-40110247-B2C0-4A15-A3B0-7BF05FE2C0E2

Q33794388-4553B385-70C3-42F2-815D-CAEA910D3A9B

P2888

Q33794388-26F526B8-CCA4-4C87-A9D6-4CD59443B247

P304

Q33794388-B5DA9D26-5C95-42CA-B990-7C4FC8CCF4F4

P31

Q33794388-152774C6-0AD3-47A3-9102-F5D7045523F2

Q33794388-DABACBCD-CFF6-458B-BE6E-780E2E335ADD

P356

Q33794388-223D58F0-9DE2-4558-B217-41226164B2EA

P433

Q33794388-4FB94D72-122D-427E-AB49-FA22AC981FC2

P478

Q33794388-65B3159D-09BD-4EF4-BCE4-580D46D1D109

P577

Q33794388-89802B7A-B55C-48EB-B806-9DF2B5342FA2

P5875

Q33794388-E5D76CA1-6297-4FC0-A899-E707B5492566

P698

Q33794388-E7F2105B-BD84-44D9-8A5D-4A50642120BF

P921

Q33794388-F643345B-6C7F-404D-B9D9-146C907E96FB

P932

Q33794388-39FCA87D-7894-4A23-9A6A-DBD52F081C5C

P356

S11102-009-0206-Y

P1433

P1476

Management of acromegaly in Latin America: expert panel recommendations

@en

P2093

Alejandro Cob

http://www.w3.org/2001/XMLSchema#string

Ana Laura Espinosa-de-los-Monteros

http://www.w3.org/2001/XMLSchema#string

Ariel Barkan

http://www.w3.org/2001/XMLSchema#string

Gloria Garavito

http://www.w3.org/2001/XMLSchema#string

Lesly Portocarrero

http://www.w3.org/2001/XMLSchema#string

Marcello D Bronstein

http://www.w3.org/2001/XMLSchema#string

Michael Sheppard

http://www.w3.org/2001/XMLSchema#string

Mirtha Guitelman

http://www.w3.org/2001/XMLSchema#string

Moisés Mercado

http://www.w3.org/2001/XMLSchema#string

Monica R Gadelha

http://www.w3.org/2001/XMLSchema#string

P2860

Dopamine agonists and the risk of cardiac-valve regurgitation

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal.

Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.

Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group.

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.

Improvement of acromegaly after octreotide LAR treatment.

Long-term mortality after transsphenoidal surgery for Cushing disease.

Criteria for cure of acromegaly: a consensus statement.

Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity.

P2888

s11102-009-0206-y

P304

168-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11102-009-0206-Y

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38060437

http://www.w3.org/2001/XMLSchema#string

P698

19882249

http://www.w3.org/2001/XMLSchema#string

P921

P932

2855858

http://www.w3.org/2001/XMLSchema#string